All Articles

A new understanding of ribonucleic acid’s activity in cells may lead to breakthroughs in ophthalmic treatment.
A rundown of the most interesting research in a variety of subspecialties presented at this year’s ARVO meeting.
Section Editor Ryan Bouchard interviews John Berdahl, MD.
Phase 3 Allergy Program Establishes Clinical Indication Expansion Strategy of DEXTENZA™
The placid ocular surface is actually teeming with life that might hold the secret to treating ophthalmic disease.
Allergic conjunctivitis is a common and potentially debilitating condition affecting the conjunctiva, eyelids and cornea, and it is often associated with nonocular symptoms and signs of rhinitis or sinusitis.
See you next year in Seattle!
Collaboration Allows Portola to Advance Product Candidates Outside of Core Focus
Ophthalmic Product Development Insights

Pages